Advice

following a full submission

Infliximab (Remsima®) is accepted for restricted use within NHS Scotland.

Indication under review: Rheumatoid arthritis: in combination with methotrexate, for the reduction of signs and symptoms as well as improvement in physical function in:

  • adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate has been inadequate;
  • adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.


Infliximab (Remsima®) is also indicated in the following conditions: adult and paediatric Crohn’s disease and ulcerative colitis; adult psoriatic arthritis, psoriasis and ankylosing spondylitis.1

SMC restriction: Infliximab (Remsima®) is accepted for use in line with the current SMC and Healthcare Improvement Scotland advice for the reference product infliximab [Remicade®].

A phase III, randomised, double-blind, parallel-group study demonstrated similar efficacy and safety of biosimilar infliximab with originator infliximab in patients with rheumatoid arthritis.

Infliximab (Remsima®) is a biosimilar product to a reference product (infliximab [Remicade®]).

The British National Formulary advises that it is good practice to prescribe biologic medicinal products by brand name.

Download detailed advice184KB (PDF)

Download

Medicine details

Medicine name:
infliximab (Remsima)
SMC ID:
1006/14
Indication:
Rheumatoid arthritis: in combination with methotrexate, for the reduction of signs and symptoms as well as improvement in physical function in: adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate has been inadequate; adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.
Pharmaceutical company
Celltrion Healthcare Hungary Kft
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full
Status
Superseded
Date advice published
09 March 2015